info@oncologyventure.com

First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer

CAMBRIDGE, Mass. and HOERSHOLM, Denmark, June 26, 2018 — Oncology Venture US Inc., Oncology Venture AB (OV:ST) (“OV”) and Medical...

June 1, 2018, 4:09pm CDT: Oral Presentation of 2X-121 Abstract at ASCO 2018

Ruth Plummer, MD, PhD, FRCP, will present an abstract describing the first-in-human Phase 1 study of 2X-121, an investigational PARP 1/2...